Skip to content

Effect of Persiyawashan in Polycystic Ovarian Syndrome

Efficacy of Persiyawashan on ovarian volume in Polycystic Ovarian Syndrome A randomized controlled study - NIL

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/06/069385
Enrollment
72
Registered
2024-06-24
Start date
Unknown
Completion date
Unknown
Last updated
2024-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N839- Noninflammatory disorder of ovary,fallopian tube and broad ligament, unspecified

Interventions

Intervention1: Persiyawashan (Adiantum capillus veneris Linn.): Decoction of parsiyawashan 10 gms will be prepared as per standard preparation. Orally BD before food. 5day before expected date of men

Sponsors

National Institute of Unani Medicine
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Both unmarried and married female patients between 18-42 year of age. Fulfilling Rotterdam’s criteria (clinical hyperandrogenism or biochemical hyperandrogenism, evidence of oligo-amenorrhea, polycystic appearing-ovarian morphology on ultrasound)

Exclusion criteria

Exclusion criteria: Patients with systemic Hypertension, Diabetes mellitus and endocrine diseases like thyroid dysfunction and hepatic disorders. Pregnant and lactating women. Patient on hormonal contraceptives (use within 3 months). Patients with history of malignancies, endometrial tuberculosis, uterine fibroid more than 3 centimeter, other ovarian cyst more than 2 centimeters

Design outcomes

Primary

MeasureTime frame
Change in ovarian volume, Modified Ferriman Gallwey score, acanthosis nigricans, SF 12 QOL, BMI.Timepoint: 0,1,2,3,4 months

Secondary

MeasureTime frame
Menstrual regulation.Timepoint: 0,1,2,3,4 months

Countries

India

Contacts

Public ContactProf Wajeeha Begum

National Institute of Unani Medicine

drwajeehanium@gmail.com9972550185

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026